Burgdorf – Ypsomed partners with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach. During the first half of 2022, this easy-to-use loop solution will be launched for the mylife YpsoPump system, starting in selected major countries in Europe and followed by other territories in the course of the year. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX Android mobile application and are enabled to algorithm-based insulin delivery support including bolus from the personal smartphone.
The partnership with CamDiab Ltd provides a world-leading, adaptive, hybrid closed-loop solution which enables users of the mylife YpsoPump to better manage their glucose levels and to benefit from a uniquely adapting and responsive control algorithm running on a smartphone. The mylife CamAPS FX Android mobile application is compatible with the Dexcom G6 CGM and is the first CE-marked algorithm on a mobile app. It automatically adjusts insulin delivery on the insulin pump based on glucose readings from the Dexcom G6 CGM. The control algorithm has been tested extensively in clinical trials and the results have been published in world-leading medical journals. The app is available for use in Europe, approved for ages one year and older including pregnancy. For increased privacy and convenience, users are able to deliver a meal-time bolus directly from their personal smartphone. The easy-to-use user interface ensures everyday suitability with high discretion and facilitates high adherence and improved therapy outcomes.
We are very excited to work together with CamDiab Ltd, a trailblazer in developing interoperable loop systems. Together, we can make a step further in achieving our common goal, making life of people living with diabetes as easy as possible. We are looking forward to rolling out this solution in Europe over the coming months, first on Android and then also on iOS, says Simon Michel, CEO of Ypsomed.
Personalised and self-learning
The mylife CamAPS FX Android mobile application is personalised and constantly learns and quickly adapts to ever changing insulin needs. It adjusts to diurnal and day-to-day variations in insulin requirements and compensates for over- and under-dosing of the mealtime bolus. If a user consistently over- or underestimates carbohydrates, the algorithm adjusts insulin delivery accordingly to prevent low and high glucose levels. This enables a safe and efficient use in all life circumstances including pregnancy. With this automated insulin delivery system, the user has less work and interactions with the insulin pump, resulting in more freedom in everyday life, increased adherence and better quality of life.
Many years of research went into our hybrid closed-loop solution – and we are thrilled to bring in our expertise on to this project with Ypsomed, a leader in innovation in delivery systems for liquid drugs. We share a common goal, and that is to help people with diabetes and their families to live better lives – we are excited that technology and innovation can contribute to a better and healthier future, says Roman Hovorka, Director CamDiab Ltd.
CamDiab Ltd is a digital health and personalized medicine company focused on the design, development, and commercialization of its world leading, interoperable CamAPS FX closed loop app. The CamAPS FX is designed to use adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. For further information, visit www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter @CamAPS_FX.